Market Snapshot
S&P Futures
3,809.5
Dow Futures
30,868
Nasdaq Futures
11,633.25
Allarity Therapeutics, Inc. (ALLR) stock declined over -19.02% intraday to trade at $1.32 a share on NASDAQ. The stock opened with a loss of -27.07% at $1.61 and touched an intraday high of $1.61, falling -19.02% against the last close of $1.63. The stock went to a low of $1.22 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-06-30 | $1.61 | $1.61 | $1.22 | $1.32 | 178,261 |
2022-06-29 | $1.81 | $1.84 | $1.6 | $1.63 | 53,100 |
2022-06-28 | $1.77 | $1.92 | $1.76 | $1.84 | 75,400 |
2022-06-27 | $1.82 | $1.82 | $1.76 | $1.77 | 41,900 |
2022-06-24 | $1.77 | $1.85 | $1.76 | $1.79 | 59,300 |
2022-06-23 | $1.8 | $1.87 | $1.76 | $1.76 | 41,800 |
2022-06-22 | $1.76 | $1.86 | $1.76 | $1.82 | 104,400 |
2022-06-21 | $1.78 | $1.8 | $1.74 | $1.78 | 38,700 |
2022-06-17 | $1.6 | $1.76 | $1.59 | $1.72 | 72,300 |
2022-06-16 | $1.7 | $1.722 | $1.54 | $1.6 | 65,800 |
Employees-
Beta-
Sales or Revenue0
5Y Sales Change-
Fiscal Year Ends2020-12-30
SectorHealth Care
IndustryBiotechnology
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 development for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the 3rd line treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of 2nd line metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 development for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 development for metastatic breast cancer and/or glioblastoma multiforme. The company was founded in 2004 and is headquartered in Cambridge, Massachusetts.
Allarity Therapeutics, Inc. (NASDAQ: ALLR) stock price is $1.32 as of the last check on Thursday, June 30. During the trading session, ALLR stock reached the peak price of $1.61 while $1.22 was the lowest point it dropped to.
The NASDAQ listed ALLR is part of Biotechnology industry that operates in the broader Health Care sector. Allarity Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology.
Mr. Stefano R. Carchedi
CEO, Pres & Director
Mr. Jens Erik Knudsen CPA, M.B.A.
Chief Financial Officer
Mr. James G. Cullem J.D.
Chief Bus. Officer
Dr. Marie Foegh DrSc, M.D.
Chief Medical Officer
ALLR stock traded closed the last session at $1.32, which is $-0.31 or -19.02% lower than its previous close of $1.63. ALLR's current trading price is 20.00% lower than its 52-week high of $18.20 where as its distance from 52-week low of 1.10% is -92.75%.
Number of ALLR employees currently stands at -. ALLR operates from 210 Broadway, Suite 201, Cambridge, MA 02139, United States.
Official Webiste of $ALLR is: https://www.allarity.com
ALLR could be contacted at ALLR operates from 210 Broadway, Suite 201, Cambridge, MA 02139, United States, or at phone #401 426 4664 and can also be accessed through its website.
ALLR stock volume for the day was 178,261 shares while in the previous session number of ALLR shares traded was 178,261 . The average number of ALLR shares traded daily for last 3 months was 149.12 Thousands.
The percentage change in ALLR stock occurred in the recent session was -19.02% while the dollar amount for the price change in ALLR stock was $-0.31.
In the recent session, the day high for ALLR stock was $1.61 while the low for ALLR stock touched on the day was $1.22.
The market value of ALLR currently stands at 12.03 Million with its latest stock price at $1.32 and 8.29 Million of its shares outstanding.